NASDAQ$APGE
Apogee Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported first quarter financial results and pipeline progress.
Apogee Therapeutics reported its first quarter financial results, highlighting the initiation of a Phase 2 clinical trial for APG777, dosing of the first participant in the Phase 1 trial of APG808, and nomination of a development candidate for APG990. The company's cash runway extends into 2028, supported by $816 million in cash, cash equivalents and marketable securities.
- Initiated a Phase 2 clinical trial of APG777 in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concept data expected in 2H 2025.
- Dosed first participant in Phase 1 clinical trial of APG808 for the treatment of chronic obstructive pulmonary disease and other inflammatory diseases, with interim Phase 1 data expected in 2H 2024.
- Nominated development candidate for APG990, with a Phase 1 trial expected to initiate in 2H 2024.
- Cash, cash equivalents and marketable securities totaled $816 million, providing runway into 2028.
Headline financials
Revenue & EPS history
Apogee · Revenue · Quarterly
$0
Forward guidance
Apogee Therapeutics is advancing its pipeline with multiple clinical trials planned and data readouts expected in the near term. The company's strong financial position supports operations into 2028.
Tailwinds
- Phase 2 trial of APG777 initiated with data expected in 2H 2025.
- Phase 1 trial of APG808 initiated with interim data expected in 2H 2024.
- Phase 1b readout for APG808 in asthma to follow in the first half of 2025.
- Phase 2 trial in COPD planned in the same year.
- Phase 1 trial for APG990 expected to initiate in 2H 2024.
Headwinds
- Clinical trial outcomes are subject to various risks and uncertainties.
- The relationship between preclinical and clinical study results is unpredictable.
- Regulatory filings and approvals are not guaranteed.
- Global macroeconomic conditions and related volatility.
- Potential delays or setbacks in research and development programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2023
+5.6%
Avg return
Earnings day
+9.2%
Avg return
5 days after
+10.9%
Avg return
30 days after
53%
8 / 15 earnings
Positive
+59.8%
Q4 2023
Best reaction
-12.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.2% | +4.4% | +20.3% | |
| Q3 2025 | +3.8% | +19.7% | +39.0% | |
| Q2 2025 | -2.2% | +5.4% | +5.9% | |
| Q1 2025 | -0.0% | -1.1% | +9.4% | |
| Q4 2024 | -0.2% | +14.9% | +20.3% | |
| Q3 2024 | -12.7% | -21.8% | -26.7% | |
| Q2 2024 | +9.7% | +11.7% | +25.0% | |
| Q1 2023 | +1.5% | -5.5% | -16.7% | |
| Q1 2024 | +1.5% | -5.5% | -16.7% | |
| Q4 2023 | +59.8% | +61.8% | +41.4% | |
| Q3 2023 | +12.8% | +20.6% | +45.9% | |
| Q3 2022 | +12.8% | +20.6% | +45.9% | |
| Q4 2022 | -1.1% | +4.0% | -9.6% | |
| Q2 2022 | -1.1% | +4.0% | -9.6% | |
| Q2 2023 | -1.1% | +4.0% | -9.6% | |
| Q1 2022 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro